Shares of Hims & Hers Health Inc. (HIMS) tumbled 10.77% in after-hours trading on Monday following the release of its second quarter 2025 financial results. The telehealth company's stock decline came despite beating earnings estimates, as revenue fell short of expectations.
Hims & Hers reported Q2 revenue of $544.8 million, marking a substantial 73% increase year-over-year. However, this figure missed the IBES estimate of $551.6 million. On a positive note, the company's earnings per share (EPS) of $0.17 surpassed the expected $0.14, while adjusted EBITDA of $82.2 million also beat the estimate of $73.5 million. The number of subscribers grew by 31% to over 2.4 million compared to the previous year.
Despite the mixed results, Hims & Hers maintained its full-year 2025 guidance, projecting revenue between $2.3 billion and $2.4 billion and adjusted EBITDA ranging from $295 million to $335 million. The company also faces an ongoing securities class action lawsuit related to allegations of promoting and selling knockoff versions of the weight-loss drug Wegovy, which may be contributing to investor concerns. As the telehealth sector continues to evolve, investors will be closely watching how Hims & Hers navigates these challenges and capitalizes on its growing subscriber base.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。